ORANGEBURG, N.Y., Feb. 9, 2011 (GLOBE NEWSWIRE) -- Vision-Sciences, Inc. (Nasdaq:VSCI) today announced results for its third quarter and first nine months of fiscal 2011, ended December 31, 2010. For the third quarter of fiscal 2011, net sales were $2.7 million, a sequential increase of $0.4 million, or 17%, from the second quarter of fiscal 2011, ended September 30, 2010, primarily due to higher sales of our urology endoscopes and EndoSheath® disposables, our ENT ("ear, nose, and throat") endoscopes, and increased repair, peripheral and accessory sales. These same revenues represent an increase of $0.1 million, or 4% from the third quarter of fiscal 2010, ended December 31, 2009, primarily due to higher sales of our urology endoscopes and EndoSheath disposables. Pro forma for the exclusion of sales to Medtronic, which, effective April 1, 2010, no longer served as our distributor of ENT endoscopes, net sales for the third quarter of fiscal 2011 represented an increase of $1.1 million, or 66%, from the third quarter of fiscal 2010.
Vision-Sciences, Inc. Announces $7.7 Million In Revenue For The First Nine Months Of Fiscal 2011
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.